PatientsVille.com Logo

MUSCULAR WEAKNESS and ACIPHEX

PatientsVille

MUSCULAR WEAKNESS Symptoms and Causes

Myasthenia gravis is a disease that causes weakness in your voluntary muscles. These are the muscles that you control. For example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. You can also have weakness in other muscles. This weakness gets worse with activity, and better with rest.

Myasthenia gravis is an autoimmune disease. Your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. This makes your muscles weaker.

Other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. Tests used to make a diagnosis include blood, nerve, muscle, and imaging tests.

With treatment, the muscle weakness often gets much better. Medicines can help improve nerve-to-muscle messages and make muscles stronger. Other drugs keep your body from making so many abnormal antibodies. These medicines can have major side effects, so they should be used carefully. There are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. Sometimes, surgery to take out the thymus gland helps.

Some people with myasthenia gravis go into remission. This means that they do not have symptoms. The remission is usually temporary, but sometimes it can be permanent.

NIH: National Institute of Neurological Disorders and Stroke

Check out the latest treatments for MUSCULAR WEAKNESS

MUSCULAR WEAKNESS treatment research studies

ACIPHEX clinical trials, surveys and public health registries


Find Drug Side Effect reports



ACIPHEX Side Effects

Pain (30)
Headache (27)
Fatigue (24)
Nausea (24)
Dizziness (23)
Dyspnoea (22)
Chest Pain (22)
Diarrhoea (21)
Abdominal Pain Upper (19)
Pneumonia (18)
Cholecystitis Chronic (18)
Hypertension (17)
Oedema Peripheral (16)
Anxiety (16)
Cholelithiasis (16)
Myocardial Infarction (16)
Pruritus (15)
Pain In Extremity (14)
Depression (14)
Fall (13)
Loss Of Consciousness (13)
Dyspepsia (13)
Death (13)
Gallbladder Disorder (12)
Abdominal Pain (12)
Weight Decreased (12)
Asthenia (11)
Cerebrovascular Accident (11)
Feeling Abnormal (10)
Chronic Obstructive Pulmonary Disease (10)
Hypoaesthesia (10)
Rash (10)
Insomnia (10)
Pulmonary Embolism (10)
Paraesthesia (10)
Palpitations (10)
Injury (10)
Burning Sensation (9)
Muscle Spasms (9)
Chest Discomfort (9)
Arthralgia (9)
Deep Vein Thrombosis (8)
Emotional Distress (8)
Nephritis Interstitial (8)
Vomiting (8)
Cough (8)
Back Pain (8)
Cardiac Failure Congestive (8)
Condition Aggravated (8)
Coronary Artery Disease (8)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Have experienced polyneuropathy after taking aciphex this past year

I am a 28 year old female who was diagnosed 3 years ago with a hiatal hernia, 9 stomach ulcers and constant gastritis. They put me on aciphex. I have been on it ever since as it is the only thing that stops the pain. Just recently (within the

I have been taking aciphex for 7 days dont seem to be any different wonder if it takes a bit for it to work anyone else have this problem.

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

<strong></strong><span style='color: #ffa500;'>I am experiencing severe muscular <span style='color: #0000ff;'>pain/muscle tighteningin the diaphragm and sometimes &

<strong>I am on Cipralex now for about 2-3 months -10mg in the morning for depression, and now am experiencing chronic muscle weakness, chronic pain in both wrists and left hip, chronic fatigue, nausea, constant dizziness, tremors/shaky, restle

2 patients given thiocolchicoside reported of muscular stiffness,uneasiness,insomnia,breathlessness and feeling of restlessness, 2 out of 5 patients have reported such experiences after consuming thiocolchicoside.i strongly recommend to withdraw this

Afeccion cardiaca,pues a pesar de hacer ejercicio se me bloquearon las arterias,por mucho colesterol y tuvieron que hacerme un cateterismo, tengo once aos de que me detectaron la enfermedad. He perdido masa muscular pero nado ycamino dos o tres ve

After 18 months, great fatigue and muscular pain. Is this due to Intragam? consultant thinks I'm being fussy

After a 1 week course of Trimethoprim 200mg. I developed mild thrush on day3, muscle weakness for 1 day on the day after completion of the course and, 3 days after completion generalised urticaria. Not sure if this is delayed sensitivity but I assu

After finnishing the dose for Artequin I started feeling, body twitching, weakness,dizzness, body cramps, headache, neck pain, sore joints and now am at my sixth day after the dose and still experiencing the side effects..

After my first injection on Friday three weeks ago I experienced numbness and weakness Sunday night after injection along with a fever and night sweats. Went back to doctor on Tuesday and had an ultrasound to see if blockages or blood clots everythin

After takin tablets, i am feelimg somewhat uneasyness, feeling weakness, food intake is reduced

MUSCULAR WEAKNESS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  Comparison of Oral Rabeprazole vs. iv Omeprazole in Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding
Condition: Nonvariceal Upper Gastrointestinal Bleeding
Interventions: Drug: Intravenous Omeprazole;   Drug: Oral Rabeprazole
Outcome Measure: This study aims to compare the effect of three-day oral rabeprazole and iv omeprazole on bleeding control in patients with mild to moderate non-variceal UGIB.
2 Unknown  Comparison of Ulcer Healing in Patients Taking Rabeprazole With Different Antiplatelets
Conditions: Gastric Ulcer;   Duodenal Ulcer
Intervention: Drug: rabeprazole plus aspirin versus rabeprazole plus clopidogrel
Outcome Measures: The primary end point is treatment success (ulcer healing rate).;   The secondary end point is incidence of ulcer bleeding within 12 weeks.
3 Recruiting A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
Condition: Cancer
Interventions: Drug: Dabrafenib 150 mg twice a day (BID);   Drug: Rabeprazole 40 mg once daily (OD);   Drug: Rifampin 600 mg OD
Outcome Measures: PK assessment (Cmax) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment (tmax) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment (AUC[0-tau]) of Dabrafenib with and without Rabeprazole or Rifampin;   PK assessment of Dabrafenib co administered with rabeprazole or rifampin;   PK assessment (AUC[0-tau]) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   PK assessment (Cmax and Ctau,) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   PK assessment (tmax) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib;   Ratio of metabolite to Dabrafenib;   Safety and tolerability assessment to measure vital signs;   Safety and tolerability assessment for 12-lead ECG;   Safety and tolerability assessment for laboratory tests;   Safety and tolerability assessment of dabrafenib in combination with rabeprazole or rifampin;   Concentrations of Rabeprazole in the presence of Dabrafenib;   Concentrations of Rifampin in the presence of Dabrafenib
4 Unknown  Rabeprazole Based Sequential-Concommitant Hybrid Therapies for H. Pylori Infections
Condition: Helicobacter Pylori Infection
Interventions: Drug: RA5-RACM7;   Drug: RA3-RACM7;   Drug: RA7-RACM7
Outcome Measure: Eradication rate
5 Recruiting Concomitant Therapy of H. Pylori
Condition: Gastritis, Gastric Ulcer, and Duodenal Ulcer
Intervention: Drug: amoxicillin, clarithromycin, metronidazole, rabeprazole
Outcome Measure: Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori
6 Recruiting Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food
Condition: Healthy
Interventions: Drug: palbociclib commercial free base;   Drug: famotidine;   Drug: rabeprazole;   Drug: antacid
Outcome Measures: Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)];   Maximum Observed Plasma Concentration (Cmax);   Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast);   Apparent Oral Clearance (CL/F);   Time to Reach Maximum Observed Plasma Concentration (Tmax);   Apparent Volume of Distribution (Vz/F);   Plasma Decay Half-Life (t1/2)
7 Recruiting H2RA VS PPI for the Prevention of Ulcer Bleeding Associated With Low-dose Aspirin in Patients With Very High Ulcer Risk
Condition: Peptic Ulcer Bleeding
Interventions: Drug: Rabeprazole;   Drug: Famotidine
Outcome Measures: Recurrent ulcer bleeding;   Lower GI bleeding;   serious cardiothrombotic events
8 Recruiting Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori
Condition: Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive
Intervention: Drug: Rabeprazole Sodium
Outcome Measures: Response rate of gastric low-grade MALT lymphoma by eradication of Helicobacter pylori;   Transition rate to secondary therapy for eradication of Helicobacter pylori
9 Unknown  Increased Re-eradication Rate of Helicobacter Pylori by Adding N-acetylcystein or Metronidazole to the Triple Therapy
Condition: Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
Interventions: Drug: 10RAC+acetylcystein;   Drug: 10RAC+metronidazole
Outcome Measures: Re-eradication rate;   Influence of Participant's CYP2C19 genotype on re-eradication rate
10 Unknown  Second Line Therapy for the Cure of Helicobacter Pylori (H. Pylori) Infection
Conditions: Helicobacter Infections;   Gastritis;   Gastric Ulcer;   Duodenal Ulcer
Intervention: Drug: rabeprazole, amoxicillin, clarithromycin, metronidazole
Outcome Measures: Which treatment yields the higher re-eradication rate of H. pylori infection;   Side effects
11 Recruiting The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD
Condition: Reflux Esophagitis
Intervention: Drug: Newrabell® Tablet 10mg
Outcome Measures: Time to onset of first 1Day Heartburn free, Days;   Time to onset of first 2Days Heartburn free, Days;   1Day Heartburn free days, %;   Time in Daytime of first Heartburn free, Days;   Time in Nighttime of first Heartburn free, Days;   Weekly Heartburn Improvement Rate, %;   Average Daytime and Nighttime Heartburn Score Change at W4;   Average Daytime and Nighttime Heartburn Score Change at W8
12 Unknown  A Study of the Use of High-dose Proton Pump Inhibitor for the Treatment of Gastro-oesophageal Reflux Related Non-cardiac Chest Pain - a Randomized Double-blind Placebo-controlled Study
Condition: Chest Pain
Intervention: Drug: Rabeprazole 20mg twice daily
Outcome Measures: Symptoms assessment, quality of life.;   Compliance;   Adverse effects
13 Unknown  Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment
Condition: Gastroesophageal Reflux Disease (GERD)
Interventions: Procedure: Transoral Incisionless Fundoplication;   Drug: Proton Pump Inhibitors; active control
Outcome Measures: GERD symptoms;   PPI usage;   Lower esophageal acid exposure;   Healed reflux esophagitis;   Rate of adverse events
14 Recruiting The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD
Condition: Gastroesophageal Reflux Disease
Intervention: Drug: Proton pump inhibitor (rabeprazole)
Outcome Measure: Symptom responders after PPI trials
15 Unknown  Evaluation of Antiplatelet Drug Resistance in Taiwanese With VASP & Platelet Mapping ™ Assay
Condition: 30 Healthy People
Intervention: Drug: Clopidogrel and proton pump inhibitors
Outcome Measure: Comparison of the antiplatelet drug response apparently shown in TEG & Platelet mapping assay
16 Recruiting The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients
Conditions: Non-erosive Reflux Disease;   Barrett's Esophagus
Interventions: Device: Ryodoraku;   Device: ANSWatch;   Device: UGI endoscopy;   Other: GerdQ;   Drug: PPI
Outcome Measures: gastroesophageal reflux disease questionnaire;   Upper gastrointestinal endoscopy
17 Recruiting Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy
Condition: Helicobacter Pylori Infection
Interventions: Drug: high dose dual therapy;   Drug: concomitant therapy
Outcome Measures: to compare the efficacy of 10-day concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy;   to compare the adverse effects and patient adherence of 10-day concomitant regimen versus high dose dual therapy used as atni-Helicobacter pylori rescue therapy
18 Unknown  Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
Condition: Gastroesophageal Reflux Disease
Intervention:
Outcome Measure: The incidence and severity of acid-related symptoms with GerdQ